TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $71.57.

A number of brokerages have weighed in on TMDX. Morgan Stanley boosted their target price on shares of TransMedics Group from $63.00 to $74.00 and gave the company an “equal weight” rating in a research note on Thursday, February 23rd. Cowen upped their price objective on TransMedics Group from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, February 23rd. Oppenheimer upped their price objective on TransMedics Group from $55.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, February 23rd. JPMorgan Chase & Co. upped their price objective on TransMedics Group from $67.00 to $81.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. Finally, Canaccord Genuity Group upped their price objective on TransMedics Group from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Thursday, February 23rd.

Insider Buying and Selling

In related news, VP Laura Damme sold 4,990 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $59.01, for a total value of $294,459.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Laura Damme sold 4,990 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $59.01, for a total value of $294,459.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 7,500 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $64.14, for a total transaction of $481,050.00. Following the completion of the transaction, the chief executive officer now directly owns 418,785 shares of the company’s stock, valued at approximately $26,860,869.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,528 shares of company stock valued at $12,802,477. Company insiders own 8.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $350,000. Parkman Healthcare Partners LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $1,768,000. Walleye Capital LLC bought a new position in shares of TransMedics Group during the 2nd quarter valued at about $651,000. Cubist Systematic Strategies LLC boosted its holdings in shares of TransMedics Group by 267.4% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 71,760 shares of the company’s stock valued at $2,995,000 after purchasing an additional 52,226 shares during the last quarter. Finally, Spouting Rock Asset Management LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $420,000. Institutional investors own 88.58% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $75.91 on Wednesday. The firm has a market cap of $2.44 billion, a PE ratio of -60.73 and a beta of 1.47. The company has a current ratio of 10.66, a quick ratio of 9.79 and a debt-to-equity ratio of 0.31. The firm has a fifty day simple moving average of $67.72 and a two-hundred day simple moving average of $57.65. TransMedics Group has a 1-year low of $16.70 and a 1-year high of $83.48.

TransMedics Group (NASDAQ:TMDX – Get Rating) last announced its earnings results on Wednesday, February 22nd. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The business had revenue of $31.38 million during the quarter, compared to analyst estimates of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative return on equity of 29.82%. The company’s quarterly revenue was up 224.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.46) EPS. On average, equities analysts anticipate that TransMedics Group will post -0.89 EPS for the current year.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.